CORD-19:c654596857bce9cdd64ffc51842048643107348c / 145083-145246 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/c654596857bce9cdd64ffc51842048643107348c","sourcedb":"CORD-19","sourceid":"c654596857bce9cdd64ffc51842048643107348c","text":"We have tested the in vitro activity of linezolid, telithromycin, synercid and newer fluoroquinolones against multi-drug resistant C. urealyticum clinical strains.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T1211","span":{"begin":0,"end":163},"obj":"Sentence"},{"id":"T31345","span":{"begin":0,"end":163},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T1211","pred":"source","obj":"CORD-19-Sentences"},{"subj":"T31345","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T394","span":{"begin":0,"end":163},"obj":"Sentence"}],"attributes":[{"subj":"T394","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-PD-HP","denotations":[{"id":"T207","span":{"begin":116,"end":130},"obj":"Phenotype"}],"attributes":[{"id":"A207","pred":"hp_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/HP_0020174"},{"subj":"T207","pred":"source","obj":"CORD-19-PD-HP"}]},{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T592","span":{"begin":131,"end":132},"obj":"Disease"}],"attributes":[{"id":"A592","pred":"mondo_id","subj":"T592","obj":"http://purl.obolibrary.org/obo/MONDO_0005688"},{"subj":"T592","pred":"source","obj":"CORD-19-PD-MONDO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#ec93b3","default":true},{"id":"CORD-19_Custom_license_subset","color":"#93cdec"},{"id":"CORD-19-PD-HP","color":"#e7ec93"},{"id":"CORD-19-PD-MONDO","color":"#d793ec"}]}]}}